secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001654954-25-003372
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata's XYNGARI Phase 3 acne trial meets all primary endpoints with statistical significance
--------------------------------------------------------------------------------

- STAR-1 achieved all three primary endpoints: IGA success 29.4% vs 15.2% placebo (p<0.001).
- Inflammatory lesion count reduced by 16.8 vs 13.1 (p<0.001); non-inflammatory by 17.3 vs 12.4 (p<0.001).
- XYNGARI safe and well tolerated; no serious treatment-related adverse events.
- Plans to initiate second Phase 3 STAR-2 trial in H2 2025, followed by NDA submission if positive.
- CEO cites potential for partnership discussions; over 30 million U.S. acne patients annually.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/0001654954-25-003372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-003372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer